WCG Wealth Advisors LLC Has $5.20 Million Stock Position in Novartis AG $NVS

WCG Wealth Advisors LLC raised its holdings in shares of Novartis AG (NYSE:NVS) by 128.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,705 shares of the company’s stock after acquiring an additional 21,202 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Novartis were worth $5,198,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Arlington Trust Co LLC acquired a new stake in Novartis in the 4th quarter valued at $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Novartis during the 3rd quarter worth about $33,000. South Plains Financial Inc. grew its holdings in shares of Novartis by 39.0% in the 3rd quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock valued at $35,000 after acquiring an additional 76 shares in the last quarter. Aventura Private Wealth LLC acquired a new stake in shares of Novartis in the fourth quarter valued at about $45,000. Finally, Cornerstone Planning Group LLC increased its position in shares of Novartis by 15,950.0% in the fourth quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock valued at $47,000 after acquiring an additional 319 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on NVS. Wall Street Zen cut shares of Novartis from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Morgan Stanley lifted their price objective on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research report on Thursday, March 26th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Wednesday, March 11th. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Finally, Citigroup reiterated a “buy” rating on shares of Novartis in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Price Performance

Shares of NVS opened at $148.39 on Friday. The company’s 50-day moving average is $149.60 and its 200-day moving average is $147.26. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. The firm has a market capitalization of $283.14 billion, a PE ratio of 21.26, a PEG ratio of 2.52 and a beta of 0.46. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.11 by ($0.12). The business had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business’s quarterly revenue was down .9% compared to the same quarter last year. During the same period last year, the business earned $2.28 earnings per share. Equities analysts forecast that Novartis AG will post 8.84 EPS for the current year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.